Navigation Links
Pharmasset Reports Fiscal Year End 2009 Financial Results
Date:11/25/2009

e voluntarily terminated our phase 3 studies of clevudine after we became aware of a number of spontaneous Serious Adverse Event reports and Events of Special Interest in patients receiving clevudine as prescribed therapy for HBV in South Korea, where the drug is marketed by Bukwang under the trade name Levovir, and in Hong Kong, where clinical studies were being conducted under the sponsorship of Bukwang. Given the number and severity of cases observed in South Korea and Hong Kong, we determined it was in the best interest of patients to voluntarily terminate our registration studies. All patients have now completed the follow-up period and we anticipate concluding activities by the end of the quarter ending December 31, 2009.

"Pharmasset has had a tremendous year on all fronts," said Schaefer Price, Pharmasset's President and CEO. "In collaboration with Roche, we are advancing our first in class nucleoside analog, RG7128, through a phase 2b trial and also exploring the paradigm-changing model of an all oral (interferon sparing) regimen for HCV. We reported best in class results with our second generation nucleotide analog inhibitor, PSI-7851 and anticipate starting phase 2a trials in the first quarter 2010. We believe nucleosides/tides will have an advantage in the marketplace when used with the current standard of care, due to their high RVR rates, pan-genotype activity and high barrier to resistance. In the future, as we move towards oral combinations, we believe our nucleoside/tides have the potential to be used in combination with one another and with other classes of direct acting antivirals."

Financial Results

For the fiscal year ended September 30, 2009 Pharmasset reported revenues of $13.3 million, compared with revenues of $1.9 million for the fiscal year 2008. The receipt of a $10.0 million milestone from Roche for the initiation of the phase 2b study with RG7128 led to higher reported revenues in the fiscal year
'/>"/>

Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Pharmasset Announces the Continued Enrollment of the Phase 2b Clinical Trial of RG7128 for the Treatment of Hepatitis C
2. Pharmasset to Present at Lazard Capital Markets Healthcare Conference
3. Pharmasset Reports Positive Preliminary Antiviral Data With PSI-7851 for the Treatment of Hepatitis C
4. Pharmasset to Present at Goldman Sachs and Needham Healthcare Conferences
5. Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C
6. Pharmasset Voluntarily Halts Clinical Studies with Clevudine in Hepatitis B Infected Patients
7. Pharmasset Initiates First Time in Human Study of PSI-7851 for the Treatment of Hepatitis C (HCV)
8. Pharmasset Reports Fiscal Year End 2008 Financial Results
9. Roche, InterMune and Pharmasset Announce Initiation of INFORM-1, the First Dual-Combination Clinical Trial with Oral Antivirals in Hepatitis C
10. Richard E.T. Smith, Ph.D. Joins Pharmasset as Vice President of Investor Relations and Corporate Communications
11. Pharmasset to Present at the UBS Global Life Sciences Conference on Wednesday, September 24th
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Mexico , Dec. 24, 2014  Novastem, ... of its first patient in its study for ... the American Stroke Association, ischemic strokes account for ... to enroll qualified patients in the study, entitled ... Administration of Allogeneic Mesenchymal Stem Cells and Intrathecal ...
(Date:12/24/2014)... , Dec. 24, 2014 Soligenix, ... late-stage biopharmaceutical company developing products that address unmet ... and biodefense, announced today that on December 24, ... offering. The Company raised approximately $2.3 ... intends to use the net proceeds from the ...
(Date:12/24/2014)... LONDON , December 24, 2014 /PRNewswire/ ... expected to grow at an average rate of 8.1%. ... and volume. Hip, knee and spine surgeries are the ... emerging economies they have a lower penetration. Increased number ... use of composites. Non-metallic orthopedic devices have gained popularity ...
Breaking Medicine Technology:Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 2Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 3Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 4Soligenix Announces Closing of Public Offering of Units 2Soligenix Announces Closing of Public Offering of Units 3Use of Composites in Orthopedic Industry to Reach $596 Million by 2020 2Use of Composites in Orthopedic Industry to Reach $596 Million by 2020 3
... 23, 2011 Reportlinker.com announces that ... available in its catalogue: ... Analysis of Water and Wastewater Management ... http://www.reportlinker.com/p0506839/Global-Water-Market-Outlook-Strategic-Analysis-of-Water-and-Wastewater-Management-in-the-Pharmaceutical-Industry.html?utm_source=prnewswire&utm_medium=pr&utm_campaign=Water_dis ...
... PAREXEL International Corporation (NASDAQ: PRXL ) announced ... Healthcare Conference in Palos Verdes, CA.  Josef von Rickenbach, Chairman ... PAREXEL at 4:00 p.m.  PT on Wednesday, June 8, 2011. ... available through the "Investors" section of PAREXEL,s website ...
Cached Medicine Technology:Reportlinker Adds Global Water Market Outlook: Strategic Analysis of Water and Wastewater Management in the Pharmaceutical Industry 2Reportlinker Adds Global Water Market Outlook: Strategic Analysis of Water and Wastewater Management in the Pharmaceutical Industry 3Reportlinker Adds Global Water Market Outlook: Strategic Analysis of Water and Wastewater Management in the Pharmaceutical Industry 4PAREXEL International to Present at Goldman Sachs Healthcare Conference and Jefferies Global Healthcare Conference 2
(Date:12/25/2014)... THURSDAY, Dec. 25, 2014 (HealthDay News) -- The risk ... the holidays, so you need to be extra cautious, ... Day, we see a significant increase in patients coming ... at the Suffolk County Volunteer Firefighters Burn Center of ... celebrations should be full of joy, but if not ...
(Date:12/25/2014)... -- Among early stage breast cancer patients who undergo ... percent will eventually develop leukemia as a result of ... comes from a review of more than 20,000 breast ... suggests that the risk for developing treatment-related leukemia, though ... "The frequency of bone marrow cancers such as ...
(Date:12/25/2014)... (PRWEB) December 25, 2014 AngelWeddingDress.com tries ... to the online realm. Today, the business has introduced ... a site-wide prom dress promotion. , The new prom ... each and every dress lover. They are specially designed ... 2015 prom dresses should visit its website before ...
(Date:12/25/2014)... “ SmileStix ” was featured on NewsWatch as part ... mobile applications on the iOS, Android, and Windows markets. Andrew ... the app review and shared with viewers how this is ... old saying goes, “A picture says a thousand words.” It’s ... a single image, because each picture holds a unique and ...
(Date:12/25/2014)... Newton, North Carolina (PRWEB) December 25, 2014 ... a North Carolina Retirement Community, recently showed their ... and girls of the Catawba County Parenting Network- ... meal, the 10 children gathered around the largest ... community to open presents purchased by residents of ...
Breaking Medicine News(10 mins):Health News:Don't Let Burns Mar Your Holidays 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 3Health News:Angelweddingdress 2015 Prom Dresses Online Now 2Health News:An Application to Create Custom Stickers was Featured on NewsWatch Television on December 19, 2014 2Health News:Retirement Community Residents Make Impact During Holiday Season 2
... ... ... ... WHITE PLAINS, N.Y. , March 22 Ford Motor Company President and Chief Executive Officer Alan Mulally is helping the March of Dimes give all babies a healthy ...
... Medicine (SHM) has announced that Steven Liu , MD, chairman and founder of healthcare IT company, Ingenious Med, is among the more than 150 hospitalists nationwide who have earned ... ... ... ...
... anticancer agent that preferentially kills tumor cells without apparent ... TRAIL, however, thus limiting its therapeutic potential. According to ... Journal of Cell Biology ( www.jcb.org ), ... cell differentiation protein) might represent a suitable means to ...
... GA While prevention methods appear to be helping ... antibiotic-resistant bacterium, a new superbug is on the rise, ... Network. New data shows infections from ... (MRSA) infections in community hospitals. "We found ...
... Discovery could provide target for future treatments, researchers say ... identified gene variations linked with an increased risk for ... The international research team analyzed DNA from more than ... had never smoked and found strong evidence that two ...
... ... Marketing Advisor has just surpassed the 10,000 subscriber milestone. , ... (PRWEB) March 22, 2010 -- According to ... has just surpassed over 10,000 subscribers., , ,Written and published exclusively by medical ...
Cached Medicine News:Health News:Ford CEO Asks Nation to March to Prevent Preterm Birth 2Health News:Ford CEO Asks Nation to March to Prevent Preterm Birth 3Health News:Ingenious Med Founder, Steven Liu, Earns Senior Fellow in Hospital Medicine Designation 2Health News:Ingenious Med Founder, Steven Liu, Earns Senior Fellow in Hospital Medicine Designation 3Health News:Ingenious Med Founder, Steven Liu, Earns Senior Fellow in Hospital Medicine Designation 4Health News:New superbug surpasses MRSA infection rates in community hospitals 2Health News:Medical Marketing Newsletter Reaches 10,000 Subscribers 2
... titanium alloy implants used for ... They are indicated where high ... SuperAnchor uses four Nitinol arcs ... small size. The unique design ...
... Super Revo Suture Anchor offers a simple ... mini-open rotator cuff repair. The cutting tip ... pre-threaded with two #2 strands of braided ... management are avoided with the Independent Suture ...
The Mini-Revo suture anchor is designed primarily for arthroscopic and open Bankart shoulder repair. Additional applications include other shoulder repair procedures, as well as use in small joints....
... Revo Suture Anchor offers a simple and ... rotator cuff repair. The cutting tip requires ... with two #2 strands of braided polyester ... are avoided with the Independent Suture Sliding ...
Medicine Products: